Skip to content

Hysteropexy in treatment of uterine prolapse stage >= 2: laparoscopic sacrohysteropexy versus vaginal sacrospinous hysteropexy (LAVA-trial)

Hysteropexy in treatment of uterine prolapse stage >= 2: laparoscopic sacrohysteropexy versus vaginal sacrospinous hysteropexy (LAVA-trial) - LAVA-trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON40293
Enrollment
104
Registered
2013-07-09
Start date
2013-08-02
Completion date
Unknown
Last updated
2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prolapse uterine descent

Interventions

Random allocation to vaginal sacrospinous hysteropexy or laparoscopic sacrohysteropexy.

Sponsors

Isala Klinieken
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Uterine descent POP-Q stage >= 2 requiring surgery. Patients with co-existing anterior/posterior defects or concomitant incontinence surgery (TVT-O) can be included.

Exclusion criteria

Exclusion criteria: Previous pelvic floor or prolapse surgery Wish to preserve fertility Known malignancy or abnormal cervical smears Unwilling to return for follow-up or language barriers Presence of immunological/haematological disorders interfering with recovery after surgery Contraindications for laparoscopic surgery (ileus, risk of severe adhesions) Abnormal ultrasound findings of uterus or ovaries, or abnormal uterine bleeding

Design outcomes

Primary

MeasureTime frame
Anatomical outcome and recurrence rate assessed by the POP-Q test at 1 and 5 years follow-up. Recurrence rate is defined as uterine prolapse >= 2 with symptoms.

Secondary

MeasureTime frame
Subjective improvement on urogenital symptoms and quality of life (assessed by disease-specific and quality of life questionnaires), complications following surgery, hospital stay, post-operative recovery and sexual functioning, costs-effectiveness.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)